.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Accenture
Fuji
Fish and Richardson
Merck
Queensland Health
Citi
AstraZeneca
Baxter
Teva
Dow

Generated: September 21, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Which drugs does patent 8,324,242 protect, and when does it expire?


Patent ► Subscribe protects KALYDECO and ORKAMBI and is included in three NDAs.

This patent has eighty-five patent family members in twenty-three countries.

Summary for Patent: ► Subscribe

Title:Modulators of ATP-binding cassette transporters
Abstract: The present invention relates to modulators of ATP-Binding Cassette ("ABC") transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator, compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.
Inventor(s): Ruah; Sara Hadida (La Jolla, CA), Hazlewood; Anna (San Diego, CA), Grootenhuis; Peter D. J. (San Diego, CA), Van Goor; Fredrick (San Diego, CA), Singh; Ashvani (San Diego, CA), Zhou; Jinglan (San Diego, CA), McCartney; Jason (Cardiff-by-the-Sea, CA)
Assignee: Vertex Pharmaceutical Incorporated (Cambridge, MA)
Application Number:12/351,447
Patent Claim Types:
see list of patent claims
Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Vertex Pharms Inc
KALYDECO
ivacaftor
GRANULE;ORAL207925-001Mar 17, 2015RXYesNo► Subscribe► Subscribe METHOD OF TREATING CYSTIC FIBROSIS
Vertex Pharms Inc
KALYDECO
ivacaftor
GRANULE;ORAL207925-001Mar 17, 2015RXYesNo► Subscribe► Subscribe
Vertex Pharms Inc
KALYDECO
ivacaftor
GRANULE;ORAL207925-002Mar 17, 2015RXYesYes► Subscribe► Subscribe METHOD OF TREATING CYSTIC FIBROSIS
Vertex Pharms Inc
KALYDECO
ivacaftor
GRANULE;ORAL207925-002Mar 17, 2015RXYesYes► Subscribe► Subscribe
Vertex Pharms Inc
ORKAMBI
ivacaftor; lumacaftor
TABLET;ORAL206038-002Sep 28, 2016RXYesNo► Subscribe► Subscribe
Vertex Pharms Inc
ORKAMBI
ivacaftor; lumacaftor
TABLET;ORAL206038-001Jul 2, 2015RXYesYes► Subscribe► Subscribe
Vertex Pharms Inc
ORKAMBI
ivacaftor; lumacaftor
TABLET;ORAL206038-001Jul 2, 2015RXYesYes► Subscribe► Subscribe METHOD OF TREATING CYSTIC FIBROSIS
Vertex Pharms
KALYDECO
ivacaftor
TABLET;ORAL203188-001Jan 31, 2012RXYesYes► Subscribe► Subscribe
Vertex Pharms
KALYDECO
ivacaftor
TABLET;ORAL203188-001Jan 31, 2012RXYesYes► Subscribe► Subscribe METHOD OF TREATING CYSTIC FIBROSIS
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: ► Subscribe

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
2,014,187,770► Subscribe
8,614,327Modulators of ATP-binding cassette transporters► Subscribe
8,354,427Modulators of ATP-binding cassette transporters► Subscribe
8,101,767Modulators of ATP-binding cassette transporters► Subscribe
9,090,619Modulators of ATP-binding cassette transporters► Subscribe
8,802,700Modulators of ATP-Binding Cassette transporters► Subscribe
8,829,204Modulators of ATP-binding cassette transporters► Subscribe
7,495,103Modulators of ATP-binding cassette transporters► Subscribe
8,741,925Modulators of ATP-binding cassette transporters► Subscribe
8,629,162Modulators of ATP-binding cassette transporters► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: ► Subscribe

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia2005258320► Subscribe
Australia2010249302► Subscribe
Australia2010251787► Subscribe
Australia2010251789► Subscribe
Australia2010327993► Subscribe
Australia2013204751► Subscribe
BrazilPI0511321► Subscribe
Canada2571949► Subscribe
Canada2783314► Subscribe
Canada2810655► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Mallinckrodt
Julphar
Federal Trade Commission
Cerilliant
Merck
Boehringer Ingelheim
Fish and Richardson
Citi
AstraZeneca
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot